Encora

Press Releases

Encora Therapeutics Receives FDA 510(k) Clearance for Encora X1™, a Breakthrough Wearable Device for Essential Tremor

–Encora Therapeutics, a leader in non-invasive neuromodulation technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Encora X1™. “We started Encora with a simple goal: to restore independence for movement disorder patients. Today, we are one step closer to making that vision a reality.” Alli Davanzo, co-founder and vice president, Encora TherapeuticsShare…